

1





Independent Auditor's Report

To: Vinodkumar Varma

Engagement partner

<u>vinod.varma@ss-associates.com</u> Suresh Surana & Associates LLP,

Chartered Accountants

Mumbai. India.

From: Audit Company "Aksonova & Associates" LTD

Member of Geneva Group International

Bekhterevsky lane 4B, 2nd floor,

Kyiv, 04053, Ukraine

In accordance with your *Group Reporting Instructions*, we have audited, for purposes of your audit of the consolidated financial statements GLENMARK PHARMACEUTICALS LIMITED, the Group financial statement of Glenmark Ukraine Limited Liability Company as of 31.03.2021 and for the year then ended of the accompanying Financial position statement, Statement of comprehensive income, Cash flow statement, Statement of changes in equity, Summary of statement of financial position indicators, Summary of statement of comprehensive income indicators of Glenmark Ukraine Limited Liability Company. This Group financial statement has been prepared solely to enable GLENMARK PHARMACEUTICALS LIMITED to prepare its consolidated financial statements.

Management's Responsibility for Financial statement

Management is responsible for the preparation and fair presentation of the Group financial statement in accordance with Group accounting policy for inclusion in the consolidated financial statements of GLENMARK PHARMACEUTICALS LIMITED and is intended solely for that purpose. Management is also responsible for such internal controls as necessary to enable the preparation and fair presentation of component financial information that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the Group financial statement based on our audit. We conducted our audit in accordance with ISA and Group reporting Instruction, adapted as necessary based on your instructions for purpose of your audit of the consolidated financial statements of GLENMARK PHARMACEUTICALS LIMITED.

ISA require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Financial statement is free from material misstatement. As requested by Suresh Surana & Associates LLP, we planned and performed our audit using the materiality level specified in the *Group Reporting Instructions* from Suresh Surana & Associates LLP, which is different than the materiality level that we would have used had we been designing the audit to express an opinion on the financial information of the component alone.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the component financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the component financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the component financial information in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant







accounting estimates made by management, as well as evaluating the overall presentation of the Financial statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. The conclusions reached in forming our opinion are based on the component materiality level specified by you in the context of the audit of the consolidated financial statements of the group.

Opinion

In our opinion, the Group financial statement referred to above present fairly, in all material respects based on component materiality, in accordance with *Group Reporting Instructions*. The Group financial statement are not intended to be a complete presentation of GLENMARK PHARMACEUTICALS LIMITED results of operations and financial position and do not contain all required informative disclosures.

Restriction on Use and Distribution

This Group financial statement has been prepared for purposes of providing information to GLENMARK PHARMACEUTICALS LIMITED to enable it to prepare the consolidated financial statements of the group. As a result, the financial statement is not a complete set of financial statements of Glenmark Ukraine Limited Liability Company in accordance with International Financial Reporting Standard and is not intended to present fairly, in all material respects, the financial position of Glenmark Ukraine Limited Liability Company as of 31.03.2021 or the results of its operations, or its cash flows for the year then ended in accordance with these financial reporting frameworks. The special purpose financial information may, therefore, not be suitable for another purpose.

This report is intended solely for the information and use of the management of Glenmark Ukraine Limited Liability Company and GLENMARK PHARMACEUTICALS LIMITED and Suresh Surana & Associates LLP and should not be used by anyone other than these specified parties.



Tetyana Grigorian
Director General / Audit Partner

Date: May 27, 2021



STATEMENT OF FINANCIAL POSITION	Sch	Mar 31 2021	Mar 31 2020
		UAH	UAH
ASSETS		IFRS	IFRS
Current assets			
Cash and cash equivalents	A	43 167 124	50 454 68
Restricted cash	В		
Trade receivables	C	80 189 052	68 828 884
Inventories	D	38 196 618	54 004 86
Other short-term financial assets	E	and an article	
Other current assets	F	1 675 809	10 202 53
Total current assets		163 228 602	183 490 964
Non current assets	Y DOMESTIC		
Property, plant and equipment	G	5 243 367	5 143 936
Other Intangible Assets	H	652 105	1 166 49
Right to Use Asset		26 990 753	19 122 126
Non-current tax assets	J		
Deferred tax assets	K	626 721	
Long term financial assets	1	220.21	
Total non - current assets		33 512 946	25 432 559
Total assets		196 741 548	208 923 523
EQUITY AND LIABILITIES			
Current liabilities			
Trade payables	M	70 556 484	84 529 468
Current tax liabilities	N		9 416 078
Short-term borrowings	0		
Current portion of long term borrowings	p		
Other liabilities	0	6 738 549	4 369 778
Short-term financial liabilities	R	0 730 343	7 000 711
Right to Use Liabilities	S	7 870 558	3 629 118
Total current liabilities		85 165 591	101 944 442
Non-current liabilities			
Long-term borrowings	T		96
Other liabilities	11	21 127 384	15 499 511
Long-term financial liabilities	V		
Deferred tax liabilities	К		
Total non-current liabilities		21 127 384	15 499 511
Total liabilities		106 292 975	117 443 953
Stockholders' equity		THE PROPERTY	
Share capital	w	18 538 305	18 538 305
Merger consideration, pending allotment	W		-
Share Premium	W	-	
Stock compensation reserve	W	39.	
Statutory reserve	W		
Currency translation reserve	W		
Retained earnings	W	71 910 268	72 941 265
Non Controlling Interest	W		
Total stockholders' equity		90 448 573	91 479 570
Total equity and liabilities		196 741 548	208 923 523

NOTES TO THE FINANCIAL STATEMENTS

Schedules referred to above and notes attached there to form an integral part of the Balance Sheet:

For and behalf of

Partner

Place: Kiev - Ukraine Date: May 06, 2021

STATEMENT OF COMPREHENSIVE INCOME	Sch	Mar 31 2021	Mar 31 2020
		UAH	UAH
INCOME		IFRS	IFRS
Operating Revenue	×	246 027 819	292 512 61:
Other income	Y	4 742 443	4 451 86
Total		250 770 262	296 964 47
Materials consumed	z		
Changes in Inventories of FG and WIP	Z	16 118 656	(24 176 296
Purchase of Traded Goods	Z	106 769 569	131 043 40
Employee benefit expenses	AA	51 226 375	50 339 75
Other expenses	AB	62 655 168	89 473 90
Depreciation, amortization and impairment of non-financial assets	AC	11 977 262	2 066 73
Total		248 747 030	248 747 50
Operating profit		2 023 232	48 216 97
Finance costs	AE	(3 186 533)	(754 889
Finance income	AD		
Profit/(Loss) before tax		(1 163 302)	47 462 086
Current tax expenses	AF	(494 416)	(9 416 078
Deferred tax expenses	AF	626 721	
Total Tax expenses		132 305	(9 416 078
Profit/(Loss) after tax from continuing operations		(1 030 997)	38 046 00

Telyanc brigariah Brestor General / Subit Partner

Schedules referred to above and notes attached there to form an integral part of the Balance Sheet.

Partner

Place : Kiev - Ukraine Date : May 06, 2021



CASH FLOW STATEMENT	UAH	UAH
CASH FLOW STATEMENT	Mar 31 2021	Март 31,2020
(A) Cash flow from operating activities		
Profit before tax	(1 163 302)	47 462 086
Adjustments for non cash items:		
Profit on sales of property, plant and equipment		
Depreciation	11 977 262	2 066 738
Unrealized gain on exchange fluctuation	(7 194 697)	4 264 959
Provision for Tax & Deferred Tax		
Interest expenses		362 892
Loss from the sale/write off of property, plant and equipment	(490 050)	
Prior Period Expenses Debited Directly to reserve		I I I S I I I
Cash flows from operations before changes in working capital	3 129 213	54 156 675
Changes in operating assets and liabilities		
Non current liabilities, trade payables and other current liabilities	2 368 770	2 924 267
Non current liabilities, trade payables and other current liabilities	4 241 440	3 629 118
Non current liabilities, trade payables and other current liabilities - Inter Co	(6 778 287)	35 996 939
Trade receivables and unbilled revenue	(11 360 167)	(15 200 992)
Changes in Inventories-InterCo	15 808 244	(24 176 296)
Other current assets	8 526 723	(6 233 348)
Taxes paid	(9 416 078)	(5 376 410)
Net cash generated from operating activities	6 519 859	45 719 953
B) Cash flow from investing activities		
Purchase of property, plant and equipment	(905 273)	(4 826 868)
Purchase of other intangible assets	56 817	(1 268 810)
Purchase of Right to Use Assets	(18 586 838)	(19 692 245)
Net proceeds from the sale of short term investments		
nterest received		
Jividend received		
Net cash generated from/ (used in) investing activities	(19 435 294)	(25 787 924)
C) Cash flows from financing activities		
Proceeds from issue of shares-InterCo		
Right to Use Long Term Liability	5 627 873	15 499 511
nterest paid on borrowings	-	(1 099 237)
nterest on borrowings		
Re-payment of Loan		(9 389 817)
let cash (used in)/ generated from financing activities	5 627 873	5 010 456
let change in cash and cash equivalents from continuing operations	(7 287 562)	24 942 485
CTR Adjustments	1	
let change in cash and cash equivalents	(7 287 562)	24 942 485
eash and cash equivalents at the beginning of the year	50 454 686	25 512 201
ash and cash equivalents at the end of the year	43 167 124	50 454 686

your Grigorian
for Genetal / Autit
Partner

This is the Cash Flow Statement referred to our report of even date

Partner

Place : Kiev - Ukraine Date : May 06, 2021

STATEMENT OF CHANGES IN EQUITY

Total Equity	18 538 305	34 895 258	38 046 008						•	91 479 570			(1 030 997)				100		
Total attributable to owners of parent																			
Currency translation reserve															The state of the s	1	HAND S	ATHASS G	The Age of the Party of the Par
Revaluation							16								-	S. C.	S/INTRE	AKE AKE	The second
Reserves & Surplus																			
Retain		34 895 258	38 046 008					- 4		72 941 265			(1 030 997)						
for-sale financial assets																			
APIC/Share Premium																			
Share	18 538 305									18 538 305									
Particulars	Balance as at April 1, 2020 Dividends Issue of share capital	Profit for the year Other comprehensive income:	Cash flow hedging - current year gains (losses)	reclassification to profit or loss Available-for-sale financial assets	- current year gains (losses) - reclassification to profit or loss	Difference from method change	Exchange differences on translating foreign operations Share of other comprehensive income of equity accounted investments	- reclassification to profit or loss	Total comprehensive income for the year	Balance at March 31, 2021	Dividends	Issue of share capital	Profit for the year	Other comprehensive income:	Cash flow hedging	- reclassification to profit or loss	Available-for-sale financial assets	- reclassification to profit or loss	Exchange differences on translating foreign operations

Story Duepak Charma

Particulars	Share Capital	APIC,Share Premium	Available for-sale financial	Retain	Reserves & Surplus	Revaluation	Currency translation reserve	Total attributable to owners	Total Equity
ncome tax relating to components of other comprehensive			COOCIO					of parent	
ncome									
otal comprehensive income for the sec-									
or complete neone to the year									
Balance at Mar 31 2021	18 538 305			71 010 258	C. H.				
				00701011					CO

Partner

Place: Kiev - Ukraine Date: May 06, 2021 and Sendal Hatit Partner

Director Marmin

chief heroundant

SUMMARY OF STATEMENT OF FINANCIAL POSITION INDICATORS

Schedule - A

Cash and cash equivalents

Cash and cash equivalents include the components as follows:

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Cash on hand		
Cash in current accounts	43 167 124	50 454 686
Cash in deposit accounts		
Mutual fund deposit in liquid money market Fund-in-transit		
Total	43 167 124	50 454 686

Schedule - C

Trade receivables [other receivables can be merged here, if material]

The carrying amount of trade receivables are analysed as follows:

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Accounts receivables	76 258 308	68 828 884
Inter company receivables	3 930 744	
Provision for doubtful debts		
Net trade receivables	80 189 052	68 828 884

Schedule - D

Inventories

Inventories recognised in the statement of financial position can be analysed as follows:

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Raw Materials		
Packing Material		
Semi-Finished Goods		
Finished Goods	37 886 206	54 004 862
Work-in-Process	-	
Others	310 412	
Total	38 196 618	54 004 862

Schedule - F

Other current assets

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Input taxes receivables	424 923	
Advance to Vendors		
Prepayment and other advances	1 250 886	10 202 531
Export incentives		-
Total	1 675 809	10 202 531

Partner

Place: Kiev - Ukraine Date: May 06, 2021 Schedule - G

Property, Plant and Equipment

Particulars	Mar 31 2021	Mar 31 2020
Hadio Walliamore	UAH	UAH
	IFRS	IFRS
Gross Block	8 434 220	7 528 948
less: Accumulated depreciation	3 190 853	2 385 011
Net Block	5 243 367	5 143 936
Capital work in progress		
Total	5 243 367	5 143 936

Schedule - H

Other Intangible assets

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Gross Block	2 341 467	2 398 283
less: Accumulated depreciation	1 689 361	1 231 786
Net Block	652 105	1 166 497
Capital work in progress		
Total	652 105	1 166 497

Schedule - I

Right to Use Asset

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Gross Block	38 279 083	19 692 245
less: Accumulated depreciation	11 288 332	570 120
Net Block Capital work in progress	26 990 753	19 122 126
Total	26 990 753	19 122 126

Schedule - K

Deferred tax assets and liabilities

Deferred taxes arising from temporary differences and unused tax losses are summarized as follows:

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Deferred tax assets	626 721	
Deferred tax liabilities		
Total	626 721	

Partner

Place: Kiev - Ukraine

Date: May 06, 2021

Grigorianbeneral / Aud it

Chilf Accountant

Schedule - M Trade payables

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Sundry creditors	4 616 391	84 529 468
Inter Company creditors Acceptances	65 940 093	
Total	70 556 484	84 529 468

Schedule - N

Current tax liabilities

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Provision for Wealth Tax		
Provision for Tax		9 416 078
Total		9 416 078

Schedule - Q

Other current liabilities

Other current liabilities are summarized as follows:

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Advances received from customer	2	
Income received in advance		
Actual Tax	1 322 926	-
Accrued Expenses	3 729 762	4 369 778
Share Application Money		
Liabilities with Employees	1 685 859	
Total	6 738 549	4 369 778

Schedule - S

Right to Use Liabilities

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Right to Use Lease Liability	7 870 558	3 629 118
Total	7 870 558	3 629 118

Partner

Place : Kiev - Ukraine Date : May 06, 2021

chief recountant Orlow Sitlana

Schedule - U

Other liabilities (Non-Current)

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Other Lease liablilites	21 127 384	15 499 511
Total	21 127 384	15 499 511

Schedule - W

Particulars	Mar 31 2021	Mar 31 2020
THE CONTRACT OF THE CONTRACT O	UAH	UAH
	IFRS	IFRS
Equity attributable to owners of the parent:	The second second	
Share capital	18 538 305	18 538 305
Add- Share issued during the year	18 538 305	18 538 305
	16 536 305	10 330 303
Share application money		
Share Premium		
Stock compensation reserve	•	
Statutory Reserve		
Capital redemption reserve		
Capital reserve		
Amalgamation reserve		
Currency translation reserve		
Reserve & Surplus		
Retained earnings	200000000	24 222 221
Profit & Loss opening balance	72 941 265	34 895 258
Addition during the period		
Current period profit	(1 030 997)	38 046 008
Exchnage Fluctuation Reserve		
Components of Defined Employee benefit cost		
Transfer to General reserve		
Seneral reserve		70.044.004
	71 910 268	72 941 265
Non Controlling Interest		
Total Equity	90 448 573	91 479 570

Partner

Place: Kiev - Ukraine Date: May 06, 2021

Diretter

SUMMARY OF STATEMENT OF COMPREHENSIVE INCOME INDICATORS

Schedule - X

Income from operations

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Sale of goods and out licensing of Intangible assets other operating revenue	246 027 819	292 512 612 - -
Total	246 027 819	292 512 612

Schedule - Y Other income

Other income is summarised as follows:

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Dividend on short term investments		
Profit on sale of short term investments		
Profit on sale of fixed assets	111 938	
Exchange Gain		
Profit on Sale of Business		*
Miscellaneous income	571 319	2 156 936
Income from services	4 059 186	2 294 930
Total	4 742 443	4 451 866

Schedule - Z

Changes in Inventory of FG and WIP

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Changes in Inventory of FG and WIP	16 118 656	(24 176 296)
Total	16 118 656	(24 176 296)

Schedule - Z

Purchase of Traded Goods

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Purchase of Traded Goods	106 769 569	131 043 408
Total	106 769 569	131 043 408

Partner

Place : Kiev - Ukraine Date : May 06, 2021

Director

cairlant secondant

Schedule - AA

Employee benefit expenses

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Salaries and bonus	50 659 193	50 339 754
Contribution to provident fund and other funds		
Staff welfare expenses	567 182	
Retirement benefits	All ac	
Total	51 226 375	50 339 754

Schedule - AB

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Power, Fuel and Water charges		
Rent, Rates & Taxes	816 435	
Sales Promotion Expenses	23 704 128	45 597 06
Provision for Doubtful Debts		
Travelling expenses	1 936 571	16 540 80
Auditors remuneration	239 707	
Freight Outward		
Insurance	1 737 991	
Repairs and Maintenance	443 519	
Telephone expenses	313 417	
Other Manufacturing Expenses		
Other Employee benefits		
Product Registration Expenses		
egal & Professional fees	3 392 467	538 84
Car Rent & Fuel	5 630 366	
Other operating expenses	7 206 734	21 834 52
Test and Trials expenses	1 519 281	
Foreign Exchange loss	1 626 053	4 962 649
Conference Expensed	13 026 974	
Printing & Stationery	326 668	
Subscription		
Postage & Telegram	174 022	
lectricity Charges		
Recruitment	169 996	
abour Charges		
Regulatory Exp		
lew Product Introdu Exp		
Consumable R&D		
onsumption of stores and spares		
commission on Sales		
oss on Sale of Assets	6 042	
ank Charges	384 796	
selling & Marketing Exp	-	
Fotal	62 655 168	89 473 900

Partner

Place : Kiev - Ukraine Date : May 06, 2021 tor Orlova tant

Schedule - AC

Depreciation, amortisation and impairment of non-financial assets

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Depreciation, amortisation and impairment of non-financial assets	11 977 262	2 066 738
Total	11 977 262	2 066 738

Schedule - AE

Finance costs

Finance costs is analysed as follows:

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
- Interest expense on short term borrowings		
Term loans		*
Cash credit		
Interest Expense - Inter company		362 892
Interest Expense - Right to Use	3 186 533	391 997
Other Financial Expenses	-	-
Total	3 186 533	754 889

Schedule - AF

Income tax (expense)/credit

Particulars	Mar 31 2021	Mar 31 2020
	UAH	UAH
	IFRS	IFRS
Current income tax Deferred tax Prior period income tax	(494 416) 626 721	(9 416 078)
Total	132 305	(9 416 078)

Partner

Place: Kiev - Ukraine Date: May 06, 2021

pirector
peopal sharms

CHAN

Chief Recounter
Orlord Svillow

RELATED PARTY TRANSACTIONS

"The Group's related parties include its associates and joint venture, key management personnel and others as described below.

Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received. Outstanding balances are usually settled in cash."

1.1 Names of related parties

All related parties and nature of relationship between various related parties are summarized as below

S No.	Nature of the relationship		Related Party's Name
1.	Key Management Personnel (KMP)	1,62	
H.	Close family member of KMP with whom the Group has transactions		
III.	Other Enterprises over which KMP are able to exercise significant influence		
IV.	Associates		
٧.	Joint Ventures		

Glenmark Pharmaceuticals Limited, India

1.2 Transactions with KMP, their close family members and enterprises over which they exercise significant influence are as under:

1.3 Transactions with associates

(a) the amount of the transactions:	UAH
Goods Purchase from Glenmark Pharmaceuticals Limited, India	106 769 569
Receipt of Inter-Company Loan - UK	
Interest on Loan - UK	•
Assets Tranfer from RO to LLC	
Discount given by Glenmark Pharmaceuticals Limited, India	
Reimbursements of Regulatory & Clinical Trials (Service fees)	4 059 186
Reimbursements of Regulatory & Clinical Trials (Third Party expenses)	2 011 242
Receipt of Fresh Capital - Swiss	
(b) the amount of outstanding balances and:	
Payable to-	
Glenmark Pharmaceuticals Limited, India	65 940 372
Re-payment of Inter-Company Loan - UK	
Payable for Purchase of Asset	
Receivable from Regulatory Service agreement	3 930 744
Receivable from Glenmark Pharmaceuticals Limited, India	

1.4 Transactions with joint ventures

Partner

Place : Kiev - Ukraine Date : May 06, 2021 THEHWARK OF THE STATE OF THE ST

chief Account